All articles tagged with #otsuka
Otsuka's experimental drug sibeprenlimab showed promising results in reducing toxic protein levels in patients with IgA nephropathy, outperforming Vera Therapeutics in a Phase 3 study, with fewer serious side effects.
The FDA has approved Otsuka and Lundbeck's Abilify Asimtufii (aripiprazole) for the treatment of schizophrenia and as a maintenance therapy for adults with bipolar I. The drug only needs to be injected once every two months, adding to the growing rank of drugs for mental disorders that don't have to be taken as an oral daily treatment.
An FDA advisory committee has voted 9-1 in favor of Rexulti (brexpiprazole), a drug developed by Otsuka and Lundbeck, for the treatment of agitation associated with Alzheimer's dementia. The drug was first approved in 2015 for schizophrenia and as an adjunctive therapy to antidepressants in adults with major depressive disorder. The safety profile of the antipsychotic was on par with others, and all three placebo-controlled Phase III trials contributed to showing the efficacy in the AAD indication.